Fexofenadine in Pruritic Skin Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00261079|
Recruitment Status : Completed
First Posted : December 2, 2005
Last Update Posted : November 7, 2007
- To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate(2.5mg/g) vs prednicarbate(2.5mg/g) alone in the treatment of pruritic skin disease
- To evaluate patient's satisfaction of Allegra treatment
|Condition or disease||Intervention/treatment||Phase|
|Pruritus||Drug: Fexofenadine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||435 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease|
|Study Start Date :||April 2005|
|Actual Study Completion Date :||October 2006|
- The change of physician's assessment on pruritic score before and after 7-day treatment.
- Patient visual analogue scale change and Overall satisfaction.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00261079
|Korea, Republic of|
|Seoul, Korea, Republic of|
|Study Director:||Hyou-Young Rhim, MD||Handok Inc.|